Mereo Biopharma Group PLC at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining me at the fourth day of the Needham Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company covering both immuno-oncology and gene therapy subsectors. It's my pleasure to have with me today Mereo, entire Mereo team actually, and we'll discuss through our fireside chat pretty much with the wide variety of different programs that Mereo has.
Questions & Answers
So Denise, actually, I'll start with you here. Maybe a bit of an introduction. You know, Mereo has a bit of a complex story. And can you talk us through some of the lead assets and key milestones we should be expecting in 2023?
Great. Well, thank you for hosting us here today, Gil, really appreciate that. So let me start by simplifying the story. Mereo is a rare disease company. We have two lead
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
